

#### Synonym

CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR


#### Source

Human CXCR3 Full Length Protein-VLP(CX3-H52P4) is expressed from human 293 cells (HEK293). It contains AA Val 2 - Leu 368 (Accession # <u>P49682-1</u>).

Predicted N-terminus: Asp

## **Molecular Characterization**

Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrance Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, highconcentration proteins perfect for immunization and antibody screening.




The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.

#### Endotoxin

Less than 1.0 EU per  $\mu$ g by the LAL method.

### **Bioactivity-ELISA**



#### Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 µm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

#### Shipping

This product is supplied and shipped as sterile liquid solution with dry ice, please inquire the shipping cost.

#### Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.

\*The isotype control of empty/mock VLP (Cat. No. <u>VLP-N5213</u>) is sold separately and not included in protein, you can follow <u>this link</u> for product information.

Anti-CXCR3 Antibody, Human IgG1 Conc. (ng/mL)


Immobilized Human CXCR3 Full Length Protein-VLP (Cat. No. CX3-H52P4) at 5  $\mu$ g/mL (100  $\mu$ L/well) can bind Anti-CXCR3 Antibody, Human IgG1 with a linear range of 0.8-6 ng/mL (QC tested).

**Bioactivity-SPR** 

>>> www.acrobiosystems.com


3/24/2023

# Human CXCR3 Full Length Protein (VLP)










Anti-CXCR3 antibody immobilized on CM5 Chip can bind Human CXCR3 Full Length Protein-VLP (Cat. No. CX3-H52P4) with an affinity constant of 60.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

## **Identity-DLS**



The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

### Background

Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in antitumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

## **Clinical and Translational Updates**

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.



3/24/2023